Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Pegylated Recombinant Human Granulocyte Colony-stimulating Factor

Generic Name: Pegylated Recombinant Human Granulocyte Colony-stimulating Factor

Overview

No overview information available.

Background

No background information available.

Indication

⑴非髓性恶性肿瘤患者在接受会发生有临床意义发热性中性粒细胞减少的抑制骨髓的抗肿瘤药治疗时，使用本品可降低发热性中性粒细胞减少引起的感染发生率。 ⑵本品不用于造血干细胞移植的外周血祖细胞的动员。

Associated Conditions

No associated conditions information available.

Clinical Trials

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Phase 2

Completed

Posted: 2020/09/18

Sponsor:Mabwell (Shanghai) B...

ID:NCT04554056

Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer

Phase 2

Completed

Posted: 2020/09/09

Sponsor:

Chongqing University...

ID:NCT04542356

Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome

Not Applicable

Posted: 2020/08/05

Sponsor:

CSPC Baike (Shandong...

ID:NCT04500886

Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma

Not Applicable

Posted: 2020/08/04

Sponsor:

CSPC Baike (Shandong...

ID:NCT04497688

Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer

Not Applicable

Posted: 2020/01/23

Sponsor:

CSPC Baike (Shandong...

ID:NCT04239001

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy